High Growth Tech Stocks to Watch in October 2024 — Oct 17th, 2024

The United States market has experienced a notable upswing, rising 1.2% over the last week and 35% over the past year, with earnings projected to grow by 15% annually. In this environment, identifying high growth tech stocks involves looking for companies that not only capitalize on techno...

CPRX or STVN: Which Is the Better Value Stock Right Now? — Oct 4th, 2024

Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. There are plenty of strategies for discover...

Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024 — Oct 1st, 2024

Catalyst Pharmaceuticals, Inc. CORAL GABLES, Fla., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients ...

CPRX or STVN: Which Is the Better Value Stock Right Now? — Oct 21st, 2024

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. The best way to ...

CPRX or STVN: Which Is the Better Value Stock Right Now? — Oct 21st, 2024

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. The best way to ...

With 75% ownership of the shares, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is heavily dominated by institutional owners — Oct 10th, 2024

Key Insights Given the large stake in the stock by institutions, Catalyst Pharmaceuticals' stock price might be vulnerable to their trading decisions The top 10 shareholders own 50% of the company Insiders have sold recently To get a sense of who is truly in control of Catalyst Pharmaceu...

NewAmsterdam Pharma Stock Hits 90-Plus RS Rating — Dec 11th, 2024

NewAmsterdam Pharma shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. Continue reading View comments...

CPRX or STVN: Which Is the Better Value Stock Right Now? — Oct 21st, 2024

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. The best way to ...

CPRX or STVN: Which Is the Better Value Stock Right Now? — Oct 4th, 2024

Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. There are plenty of strategies for discover...

CPRX or STVN: Which Is the Better Value Stock Right Now? — Oct 21st, 2024

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. The best way to ...

CPRX or STVN: Which Is the Better Value Stock Right Now? — Oct 4th, 2024

Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. There are plenty of strategies for discover...

CPRX or STVN: Which Is the Better Value Stock Right Now? — Oct 4th, 2024

Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. There are plenty of strategies for discover...

CPRX or STVN: Which Is the Better Value Stock Right Now? — Oct 4th, 2024

Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. There are plenty of strategies for discover...

High Growth Tech Stocks to Watch in October 2024 — Oct 17th, 2024

The United States market has experienced a notable upswing, rising 1.2% over the last week and 35% over the past year, with earnings projected to grow by 15% annually. In this environment, identifying high growth tech stocks involves looking for companies that not only capitalize on techno...

CPRX or STVN: Which Is the Better Value Stock Right Now? — Oct 21st, 2024

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. The best way to ...

CPRX or STVN: Which Is the Better Value Stock Right Now? — Oct 21st, 2024

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. The best way to ...

High Growth Tech Stocks to Watch in October 2024 — Oct 17th, 2024

The United States market has experienced a notable upswing, rising 1.2% over the last week and 35% over the past year, with earnings projected to grow by 15% annually. In this environment, identifying high growth tech stocks involves looking for companies that not only capitalize on techno...

Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024 — Oct 1st, 2024

Catalyst Pharmaceuticals, Inc. CORAL GABLES, Fla., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients ...

With 75% ownership of the shares, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is heavily dominated by institutional owners — Oct 10th, 2024

Key Insights Given the large stake in the stock by institutions, Catalyst Pharmaceuticals' stock price might be vulnerable to their trading decisions The top 10 shareholders own 50% of the company Insiders have sold recently To get a sense of who is truly in control of Catalyst Pharmaceu...

CPRX or STVN: Which Is the Better Value Stock Right Now? — Oct 21st, 2024

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. The best way to ...

CPRX or STVN: Which Is the Better Value Stock Right Now? — Oct 4th, 2024

Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. There are plenty of strategies for discover...

Catalyst (CPRX) Upgraded to Buy: What Does It Mean for the Stock? — Oct 1st, 2024

Catalyst Pharmaceutical (CPRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The Zacks rating relies solely on...

With 75% ownership of the shares, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is heavily dominated by institutional owners — Oct 10th, 2024

Key Insights Given the large stake in the stock by institutions, Catalyst Pharmaceuticals' stock price might be vulnerable to their trading decisions The top 10 shareholders own 50% of the company Insiders have sold recently To get a sense of who is truly in control of Catalyst Pharmaceu...

NewAmsterdam Pharma Stock Hits 90-Plus RS Rating — Dec 11th, 2024

NewAmsterdam Pharma shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. Continue reading View comments...

CPRX or STVN: Which Is the Better Value Stock Right Now? — Oct 21st, 2024

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. The best way to ...

CPRX or STVN: Which Is the Better Value Stock Right Now? — Oct 4th, 2024

Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. There are plenty of strategies for discover...

CPRX or STVN: Which Is the Better Value Stock Right Now? — Oct 4th, 2024

Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. There are plenty of strategies for discover...

High Growth Tech Stocks to Watch in October 2024 — Oct 17th, 2024

The United States market has experienced a notable upswing, rising 1.2% over the last week and 35% over the past year, with earnings projected to grow by 15% annually. In this environment, identifying high growth tech stocks involves looking for companies that not only capitalize on techno...

With 75% ownership of the shares, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is heavily dominated by institutional owners — Oct 10th, 2024

Key Insights Given the large stake in the stock by institutions, Catalyst Pharmaceuticals' stock price might be vulnerable to their trading decisions The top 10 shareholders own 50% of the company Insiders have sold recently To get a sense of who is truly in control of Catalyst Pharmaceu...

Catalyst (CPRX) Upgraded to Buy: What Does It Mean for the Stock? — Oct 1st, 2024

Catalyst Pharmaceutical (CPRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The Zacks rating relies solely on...

High Growth Tech Stocks to Watch in October 2024 — Oct 17th, 2024

The United States market has experienced a notable upswing, rising 1.2% over the last week and 35% over the past year, with earnings projected to grow by 15% annually. In this environment, identifying high growth tech stocks involves looking for companies that not only capitalize on techno...

CPRX or STVN: Which Is the Better Value Stock Right Now? — Oct 21st, 2024

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. The best way to ...

CPRX or STVN: Which Is the Better Value Stock Right Now? — Oct 21st, 2024

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. The best way to ...

CPRX or STVN: Which Is the Better Value Stock Right Now? — Oct 21st, 2024

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. The best way to ...

With 75% ownership of the shares, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is heavily dominated by institutional owners — Oct 10th, 2024

Key Insights Given the large stake in the stock by institutions, Catalyst Pharmaceuticals' stock price might be vulnerable to their trading decisions The top 10 shareholders own 50% of the company Insiders have sold recently To get a sense of who is truly in control of Catalyst Pharmaceu...

Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024 — Oct 1st, 2024

Catalyst Pharmaceuticals, Inc. CORAL GABLES, Fla., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients ...

NewAmsterdam Pharma Stock Hits 90-Plus RS Rating — Dec 11th, 2024

NewAmsterdam Pharma shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. Continue reading View comments...

High Growth Tech Stocks to Watch in October 2024 — Oct 17th, 2024

The United States market has experienced a notable upswing, rising 1.2% over the last week and 35% over the past year, with earnings projected to grow by 15% annually. In this environment, identifying high growth tech stocks involves looking for companies that not only capitalize on techno...

High Growth Tech Stocks to Watch in October 2024 — Oct 17th, 2024

The United States market has experienced a notable upswing, rising 1.2% over the last week and 35% over the past year, with earnings projected to grow by 15% annually. In this environment, identifying high growth tech stocks involves looking for companies that not only capitalize on techno...

With 75% ownership of the shares, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is heavily dominated by institutional owners — Oct 10th, 2024

Key Insights Given the large stake in the stock by institutions, Catalyst Pharmaceuticals' stock price might be vulnerable to their trading decisions The top 10 shareholders own 50% of the company Insiders have sold recently To get a sense of who is truly in control of Catalyst Pharmaceu...

NewAmsterdam Pharma Stock Hits 90-Plus RS Rating — Dec 11th, 2024

NewAmsterdam Pharma shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. Continue reading View comments...

Catalyst (CPRX) Upgraded to Buy: What Does It Mean for the Stock? — Oct 1st, 2024

Catalyst Pharmaceutical (CPRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The Zacks rating relies solely on...

With 75% ownership of the shares, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is heavily dominated by institutional owners — Oct 10th, 2024

Key Insights Given the large stake in the stock by institutions, Catalyst Pharmaceuticals' stock price might be vulnerable to their trading decisions The top 10 shareholders own 50% of the company Insiders have sold recently To get a sense of who is truly in control of Catalyst Pharmaceu...

High Growth Tech Stocks to Watch in October 2024 — Oct 17th, 2024

The United States market has experienced a notable upswing, rising 1.2% over the last week and 35% over the past year, with earnings projected to grow by 15% annually. In this environment, identifying high growth tech stocks involves looking for companies that not only capitalize on techno...

CPRX or STVN: Which Is the Better Value Stock Right Now? — Oct 21st, 2024

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. The best way to ...

With 75% ownership of the shares, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is heavily dominated by institutional owners — Oct 10th, 2024

Key Insights Given the large stake in the stock by institutions, Catalyst Pharmaceuticals' stock price might be vulnerable to their trading decisions The top 10 shareholders own 50% of the company Insiders have sold recently To get a sense of who is truly in control of Catalyst Pharmaceu...

High Growth Tech Stocks to Watch in October 2024 — Oct 17th, 2024

The United States market has experienced a notable upswing, rising 1.2% over the last week and 35% over the past year, with earnings projected to grow by 15% annually. In this environment, identifying high growth tech stocks involves looking for companies that not only capitalize on techno...

CPRX or STVN: Which Is the Better Value Stock Right Now? — Oct 21st, 2024

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. The best way to ...

Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024 — Oct 1st, 2024

Catalyst Pharmaceuticals, Inc. CORAL GABLES, Fla., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients ...

CPRX or STVN: Which Is the Better Value Stock Right Now? — Oct 4th, 2024

Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. There are plenty of strategies for discover...